SINGAPORE, MAY 15, 2023 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) is pleased to announce its appointment of Dr. Mark A. Turco (Dr. Turco), M.D., F.A.C.C., as President of Genesis MedTech Intervention, North America and CEO of JC Medical, Inc. Dr. Turco will lead the commercial strategy for the Vascular Interventions and Structural Heart Franchises […]
Other News
Impulse Dynamics Announces 9,000th Patient Milestone Achieved With CCM® Therapy for Heart Failure
Momentum Continues as Depth of Clinical Experience Expands Worldwide MARLTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a worldwide milestone achievement with the 9,000th patient receiving the Optimizer® system for […]
InspireMD Announces Private Placement of Up to $113.6 Million
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention […]
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of […]
Hyperfine, Inc. Reports First Quarter 2023 Financial Results
GUILFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable, point-of-care MRI system, today announced first quarter 2023 financial results and provided a business update. “We had strong growth at Hyperfine in the […]
Supira Medical’s Percutaneous Ventricular Assist Device (pVAD) to be Highlighted During PCR Innovator’s Day and SCAI 2023
Supira’s technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device Data from the Company’s First-in-Human trial to be presented as part of the Late-Breaking Clinical Research Session […]
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — –Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action– DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent […]
Stanford Medicine Named Winner of the 2023 Hearst Health Prize in Partnership with the UCLA Center for SMART Health
$100,000 prize awarded for Stanford Medicine’s AI solution for identifying people with heart attack risk LOS ANGELES, May 12, 2023 /PRNewswire/ — The UCLA Center for SMART Health, an interdisciplinary collaborative that looks to the integrated transformation of healthcare through emergent data and technologies, and Hearst Health, a division of Hearst and leader […]
Acutus Medical Reports First Quarter 2023 Financial Results
CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the […]
Humacyte First Quarter 2023 Financial Results and Business Update
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May […]



